American College of Obstetricians and Gynecologists (ACOG): Current ACOG Guidance: NIPT Summary of Recommendations: 2024, Available at
Current ACOG Guidance | ACOG.
Batzir NA, Shohat M, Maya I. Chromosomal Microarray Analysis (CMA) a Clinical Diagnostic Tool in the Prenatal and Postnatal Settings. Pediatr Endocrinol Rev. 2015;13(1):448-454.
Dondorp W, de Wert G, Bombard Y, Bianchi DW, Bergmann C, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening.
Eur J Hum Genet. 2015;23:1438-1450. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613463/.
Gregg AR, Skotko BG, Benkendorf JL, Monaghan KG, Bajaj K,
et al. Noninvasive prenatal screening for fetal aneuploidy. June 2016 update: a position statement of the American College of Medical Genetics and Genomics (ACMG). Available at:
https://www.acmg.net/docs/NIPS_AOP.pdf.
Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen. 2002;9(1):2–6.
Olney RS, Moore CA, Khoury MJ, Erickson JD, Edmonds LD, et al. Chorionic Villus Sampling and Amniocentesis: Recommendations for Prenatal Counseling.
Morb Mortal Wkly Rep (MMWR). July 21, 1995;44(RR-9);1-12. Available at:
https://www.cdc.gov/mmwr/preview/mmwrhtml/00038393.htm.
QNatal Advanced: Test overview, Quest Diagnostics, available at
Reiss RE, Discenza M, Foster J, Dobson L, Wilkins-Haug L. Sex chromosome aneuploidy detection by noninvasive prenatal testing: helpful or hazardous?
Prenat Diagn. May 2017;37(5):515-520. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/28326560.
Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: Implications for prenatal screening and genetic counseling. Am J Med Genet A. Feb 15 2005;133A(1):31–36.
Rodeck CH, Whittle MJ. Fetal Medicine: Basic Science and Clinical Practice. Philadelphia: Churchill Livingstone; 2009.
Stokowski R, Wang E, White K, Batey A, Jacobsson B,
et al. Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies.
Prenat Diagn. December 2015;35(12):1243-1246. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057317/.